NCT00669136终止1 期
A Phase I/II Trial Testing Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma
Lisa H. Butterfield, Ph.D.2 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2009年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 2
- 试验地点
- 2
- 主要终点
- Dose Limiting Toxicity (DLT) and Phase II Recommended Dose (P2RD)
研究概览
简要总结
To evaluate the safety, toxicity and immunological effects of adjuvant administration of an experimental therapy consisting on priming with three intramuscular administrations of a plasmid expressing human AFP (phAFP) together with a plasmid expressing human GM-CSF (phGM-CSF), followed by a single intramuscular boost with an AFP adenoviral vector (AdVhAFP) to patients with locoregionally pre-treated hepatocellular carcinoma (HCC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eligible patients must have locoregionally treated HCC and have a prior AFP serum determination over the limit of normality for each laboratory.
- •This study will enroll adults over the age of
- •Have had HCC with a history of serum AFP determination above the upper limit of normality for each laboratory.
- •Both male and female patients may be enrolled. Premenopausal females who have not undergone a surgical sterilization procedure must have a negative pregnancy test prior to treatment. Sexually active females of child-bearing potential are required to use two forms of contraception, including a barrier method, for trial eligibility. Sexually active males should use an appropriate "double barrier" method of birth control (such as female use of a diaphragm, intrauterine device (IUD), or contraceptive sponge, in addition to male use of a condom.
- •Be HLA-A2.1 positive (HLA-A*0201) by DNA subtyping, or HLA-A2 positive by flow cytometry with antibodies MA2.1 and BB7.
- •Stage II to IVa HCC after locoregional therapy (surgical resection, radio-frequency ablation, cryoablation, ethanol injection, chemoembolization and radioembolization).
- •Karnofsky Performance Status greater than or equal to 70 percent.
- •No evidence of opportunistic infection in the year before enrollment.
- •Adequate baseline hematological function as assessed by the following laboratory values within 30 days prior to study entry (day -30 to 0):
- •Hemoglobin > 9.0 g/dL (patients cannot be transfusion dependent) Platelets > 50,000/mm3 Absolute Neutrophil Count (ANC) > 1,000/mm3
- •Conserved liver function with a Child-Pugh Class A or B.
- •Ability to give informed consent.
排除标准
- •Patients who meet any one of the following criteria will be excluded from study entry:
- •Any congenital or acquired condition leading to inability to generate an immune response, including concomitant immune suppressive therapy. The ability to adequately respond to recall skin test antigens will be tested before trial entry but a negative response to skin allergens will not be reason for exclusion.
- •Concomitant steroid therapy or chemotherapy, or any of these treatments < 30 days before the first vaccination.
- •Females of child-bearing potential (premenopausal and not surgically sterilized) must have a negative serum HCG pregnancy test (within Day 14 to Day 0).
- •Acute infection: any acute viral, bacterial, or fungal infection, which requires specific therapy excluding HBV or HCV. Acute therapy must have been completed within 14 days prior to study treatment.
- •HIV-infected patients (their ability to generate a cellular immune response is altered due to the CD4-dependent immunosuppressive effects of the HIV infection).
- •Patients with any underlying conditions which would contraindicate therapy with study treatment (or allergies to reagents used in this study).
- •Patients with organ allografts (they require prolonged immunosuppressive therapy).
- •Patients with high serum titers of neutralizing anti-adenoviral antibodies (positive at greater than 1:128 dilution by serum AdV blocking assay, expected to be approximately 30% of patients, they have a greatly reduced ability to respond to the AdV boost).
研究组 & 干预措施
1
Other
AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
干预措施: AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost (Drug)
结局指标
主要结局
Dose Limiting Toxicity (DLT) and Phase II Recommended Dose (P2RD)
时间窗: 6 months
Immunological response rate in PBMC as indicated by the ELISPOT assay
时间窗: 6 months
次要结局
- Disease-Free Survival (DFS)(six months)
- Immunological response rate as indicated by optional DTH(six months)
- Immunological response rate in PBMC as indicated by the tetramer assay(six months)
- Immunological response rate in lymph nodes as indicated by the ELISPOT assay(six months)
研究者
Lisa H. Butterfield, Ph.D.
Professor of Medicine, Surgery and Immunology
University of Pittsburgh
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59HIV SeronegativityHIV InfectionsNCT00000972National Institute of Allergy and Infectious Diseases (NIAID)64
已完成
1 期
Safety and Immunogenicity Study of 2 Investigational Preventive HIV VaccinesHIV InfectionsNCT01264445International AIDS Vaccine Initiative147
终止
1 期
Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1Melanoma Stage IVMelanoma Stage IIINCT04455503Evaxion Biotech A/S15
已完成
不适用
TaMoVac-01PACTR2010050002122368Swedish Institute for Infectious Disease Control120
已完成
1 期
Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIVHIV-1-infectionNCT05471076National Institute of Allergy and Infectious Diseases (NIAID)52